| |
Hematology
 |
|
Clinical Debates in Multiple Myeloma: 2009
Description
This grand rounds series, to be held at academic and community-based bone marrow transplant centers, will focus on the most pivotal current debates in MM. The program curriculum is designed to foster communication between academic and community practitioners on research results that optimize patient outcomes.
Learn More
|
|
|
|
 |
|
Multiple Myeloma: Treatment & Management Strategies 2009
Description
This grand rounds series, presented at Veteran’s Administration community-based outpatient clinics and medical centers nationwide, will focus on the most pivotal current debates in MM. A key opinion leader will first introduce the clinical debates, which will be followed by one or more case studies to stimulate treatment discussion.
Learn More
|
|
|
|
|
|
2009 Visiting Professorship Lectures for Hematology/Oncology Fellows: Multiple Myeloma
A series of 1-hour accredited educational offerings will focus on the most pivotal current topics in MM, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, myelodysplastic syndrome, and T-cell lymphoma.
Learn More
|
|
|
|
 |
|
2009 Visiting Professorship Lectures for Hematology/Oncology Fellows: Mantle Cell Lymphoma
A series of 1-hour accredited educational offerings will focus on the most pivotal current topics in multiple myeloma, MCL, follicular lymphoma, diffuse large B-cell lymphoma, myelodysplastic syndrome, and T-cell lymphoma.
Learn More
|
|
|
|
 |
|
2009 Visiting Professorship Lectures for Hematology/Oncology Fellows: Follicular Lymphoma
The goals of hematology/oncology fellowship training programs are to provide the basis for which fellows can become knowledgeable about cancer, become experienced in caring for oncology patients, and learn the necessary skills to perform quality research to provide better care for future patients.
Learn More
|
|
|
|
 |
|
2009 Visiting Professorship Lectures for Hematology/Oncology Fellows: Diffuse Large B-cell Lymphoma
The goals of hematology/oncology fellowship training programs are to provide the basis for which fellows can become knowledgeable about cancer, become experienced in caring for oncology patients, and learn the necessary skills to perform quality research to provide better care for future patients.
Learn More
|
|
|
|
 |
|
2009 Visiting Professorship Lectures for Hematology/Oncology Fellows: T-cell Lymphoma
A series of 1-hour accredited educational offerings will focus on the most pivotal current topics in multiple myeloma, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, myelodysplastic syndrome, and T-cell lymphoma.
Learn More
|
|
|
|
 |
|
2009 Visiting Professorship Lectures for Hematology/Oncology Fellows: Myelodysplastic Syndromes
A series of 1-hour accredited educational offerings will focus on the most pivotal current topics in multiple myeloma, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, MDS, and T-cell lymphoma.
Learn More
|
|
For Reference Only |
|
|
The Future Is NOW for the Treatment of Chronic Myelogenous Leukemia!
The treatment of CML dramatically changed with the introduction of imatinib, a tyrosine kinase inhibitor (TKI) that targets the BCR-ABL chromosomal abnormality—a hallmark feature of CML. Prior to the development of TKIs, the aim of treatment was to control and palliate patients with CML; now there is curative intent. With the proper selection of treatments, physicians can influence survival outcomes. Despite high response rates to imatinib, many patients with the chronic phase of CML will have persistent disease and ultimately relapse. There are several options available to patients who have relapsed or are intolerant to imatinib, including the use of second-generation TKIs such as dasatinib and nilotinib. With the introduction of these agents, several new clinical questions have emerged. Should second-generation TKIs replace imatinib as upfront therapy? What is appropriate disease monitoring? How do you treat a patient with increasing qPCR levels in the absence of a cytogenetic or hematologic relapse? What are the indications for switching to second-line therapy and what are the implications of particular mutations on the choice of second-line therapy? How long should a second-line TKI be used before trying other strategies? What is the role of stem cell transplantation? In light of such new clinical questions, this program is intended to provide attendees with a review of appropriate front-line and salvage therapies as well as strategies for effectively monitoring response to treatment. Attendees are invited to bring their own challenging CML patient cases for expert and group discussions.
|
| |
|
|
